Vaxxas and CEPI advance US$ 4.8 million programme for needle-free thermostable mRNA vaccines: Cambridge, Massachusetts Friday, January 24, 2025, 14:00 Hrs [IST] Vaxxas, a clinical ...

Serum Institute of India is planning to introduce chikungunya and monkeypox vaccines in about a year and a half and a dengue vaccine in approximately three years. The company is focusing on vaccine ...

Pet owners can take advantage of a public pet vaccination clinic also offering microchips, nail chips and more.

Vaxxas has announced that the CEPI, has approved the progression of a $7.2 million program to develop heat-stable, ...

Brisbane-based biotechnology company Vaxxas has secured approval from Coalition for Epidemic Preparedness Innovation (CEPI) ...

Vaxxas, a clinical-stage biotechnology company commercializing a novel high-density microarray patch (HD-MAP) vaccination platform, today announced that CEPI, the Coalition for Epidemic Preparedness ...

Clinical-stage Australian biotechnology company Vaxxas will receive $3.2 million from the US Biomedical Advanced Research and ...